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Abstract GARDASIL (Merck & Co., Inc., Whitehouse Sta-
tion, NJ, USA) is a quadrivalent human papillomavirus
(HPV4) vaccine. An epidemiological study was undertaken
to evaluate concerns about the potential for HPV4 vaccination
to induce serious autoimmune adverse events (SAAEs). The
vaccine adverse event reporting system (VAERS) database
was examined for adverse event reports associated with vac-
cines administered from January 2006 through December
2012 to recipients between 18 and 39 years old with a listed
residence in the USA and a specified female gender. It was
observed that cases with the SAAE outcomes of gastroenter-
itis (odds ratio (OR)=4.6, 95% confidence interval (CI)=1.3–
18.5), arthritis (OR=2.5, 95 % CI=1.4–4.3), systemic lupus
erythematosus (OR=5.3, 95 % CI=1.5–20.5), vasculitis
(OR=4, 95 % CI=1.01–16.4), alopecia (OR=8.3, 95 % CI=
4.5–15.9), or CNS conditions (OR=1.8, 95 % CI=1.04–2.9)
were significantly more likely than controls to have received
HPV4 vaccine (median onset of SAAE symptoms from 6 to
55 days post-HPV4 vaccination). Cases with the outcomes of
Guillain-Barre syndrome (OR=0.75, 95 % CI=0.42–1.3) or
thrombocytopenia (OR=1.3, 95 % CI=0.48–3.5) were no
more likely than controls to have received HPV4 vaccine.
Cases with the general health outcomes of infection (OR=
0.72, 95 % CI=0.27–1.7), conjunctivitis (OR=0.88, 95 %
CI=0.29–2.7), or diarrhea (OR=1.01, 95 % CI=0.83–1.22)
were no more likely than controls to have received HPV4
vaccine. Previous case series of SAAEs and biological plau-
sibility support the observed results. Additional studies should
be conducted to further evaluate the potential biological mech-
anisms involved in HPV4 vaccine-associated SAAEs in ani-
mal model systems, and to examine the potential
epidemiological relationship between HPV4 vaccine-
associated SAAEs in other databases and populations.
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Introduction
GARDASIL (Merck & Co., Inc., Whitehouse Station, NJ,
USA) is a quadrivalent human papillomavirus (HPV4) vac-
cine prepared from the purified virus-like particles (VLPs) of
the major capsid (L1) protein of HPV types 6, 11, 16, and 18
[1]. The L1 proteins are produced by separate fermentations in
recombinant Saccharomyces cerevisiae and self-assembled
into VLPs. The fermentation process involves growth of
S. cerevisiae on chemically defined fermentation media which
include vitamins, amino acids, mineral salts, and carbohy-
drates. The VLPs are released from the yeast cells by cell
disruption and purified by a series of chemical and physical
methods. The purified VLPs are adsorbed on preformed
aluminum-containing adjuvant (amorphous aluminum
hydroxyphosphate sulfate). The HPV4 vaccine is a sterile
liquid suspension that is prepared by combining the adsorbed
VLPs of each HPV type and additional amounts of the
aluminum-containing adjuvant and the final purification buff-
er. HPV4 is a sterile suspension for intramuscular administra-
tion. Each 0.5 mL dose contains approximately 20 μg of HPV
6 L1 protein, 40 μg of HPV 11 L1 protein, 40 μg of HPV 16
L1 protein, and 20 μg of HPV 18 L1 protein. Each 0.5 mL
dose of the vaccine contains approximately 225 μg of alumi-
num, 9.56 mg of sodium chloride, 0.78 mg of L-histidine,
50 μg of polysorbate 80, 35 μg of sodium borate, <7 μg yeast
protein, and water for injection. The product does not contain
a preservative or antibiotics. In June 2006, the US Food and
Drug Administration (FDA) approved a regimen of three
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HPV4 injections given over 6 months to women between the
ages of 9 and 26 years of age and the advisory committee on
immunization practices (ACIP) subsequently recommended
routine HPV4 vaccination for girls who are 11–12 years old
[2].
It was previously described that the etiology of autoim-
mune diseases is still not completely clear but genetic, immu-
nological, hormonal, and environmental factors are consid-
ered to be important triggers [3]. Most often, autoimmunity is
not followed by clinical symptoms unless an additional event
such as an environmental factor favors overt expression.
Many environmental factors are known to affect the immune
system and may play a role as triggers of the autoimmune
mosaic, such as bacterial, viral, and parasitic infections. These
are known to induce and exacerbate autoimmune diseases,
mainly by the mechanism of molecular mimicry. The question
of a connection between vaccination and autoimmune illness
has long been debated in the literature and is surrounded by
controversy [4], but it was suggested that the same mecha-
nisms that act in infectious invasion of the host apply equally
to the host response to vaccination [3]. As recently reviewed
[5], the introduction of HPV vaccine was associated with
several cases of onset or exacerbations of autoimmune dis-
eases following immunization in the literature and
pharmacovigilance databases, triggering concerns about its
safety. The purpose of the present study was to conduct an
epidemiological study of the vaccine adverse event reporting
system (VAERS) to evaluate concerns about the potential for
HPV4 vaccination to induce serious autoimmune adverse
events (SAAEs).
Materials and methods
The VAERS is an epidemiological database that has been
maintained jointly by the US Centers for Disease Control
and Prevention (CDC) and FDA since 1990 as a surveillance
tool to evaluate vaccine safety. Specific adverse events fol-
lowing vaccination are required to be reported to this database
as mandated by law, but other adverse events that occur
following vaccine administration are passively reported to
VAERS. The VAERS Working Group of the CDC has previ-
ously acknowledged that less than 5 % of the total adverse
events reported to VAERS are reported by parents. Specific
serious adverse events and deaths reported to VAERS are
followed-up by the CDC/FDA. The VAERS Working Group
of the CDC and the FDA have repeatedly analyzed and
published epidemiologic studies based upon VAERS [6, 7].
The VAERS Working Group notes that VAERS is simple
to use, flexible by design, and the data are available in a timely
fashion, but it also warns that the potential limitations may
include systematic error due to underreporting, erroneous
reporting, frequent multiple exposures, multiple outcomes,
and lack of precise denominators. In addition, when evaluat-
ing data from VAERS, it is important to note that, for any
reported event, no cause and effect relationship has been
established. VAERS is interested in all potential associations
between vaccines and adverse events. Therefore, VAERS
collects information on any adverse event following vaccina-
tion reported by an individual associating the adverse event
with vaccination, be it coincidental or truly caused by a
vaccine [6, 7].
Determining the population at risk
An analysis of the VAERS updated through February 2014
was undertaken using the CDC Wonder online computer
interface (http://wonder.cdc.gov/vaers.html) and MedAlerts
online computer interface (http://www.medalerts.org/
vaersdb/index.php). These portals provide a direct method
for independent investigators to rapidly analyze up-to-date
data in VAERS. Adverse event reports associated with vac-
cines administered from January 2006 through December
2012 to recipients between 18 and 39 years old with a listed
residence in the USA and a specified female gender were used
to identify cases and controls in the present study. Overall, a
total of 22,011 adverse event reports in females were exam-
ined in the present study, and these adverse event reports were
reported to VAERS following administration of HPV4 or any
other vaccine(s).
Determining cases
The SAAE cases were selected from the 22,011 total adverse
event reports in females examined in the present study and
were defined with outcomes specified as gastroenteritis
(VAERS code: 10017888), arthritis (VAERS codes:
10003246 or 10039073), Guillain-Barre syndrome (VAERS
code: 10018767), thrombocytopenia (VAERS codes:
10043554 or 10043561), systemic lupus erythematosus
(VAERS code: 10042945), vasculitis (VAERS code:
10047115), alopecia (VAERS code: 10001760), and central
nervous system (CNS) conditions (VAERS codes: 10028245
or 10012305 or 10030942 or 10028524 or 10028527). In
addition, general health outcome cases were selected from
the 22,011 total adverse event reports in females examined
in the present study and were defined with outcomes specified
as infection (VAERS code: 10021789), conjunctivitis
(VAERS code: 10010741), and diarrhea (VAERS code:
10012735). Table 1 summarizes the total number of cases
for each type of outcome examined in VAERS.
Determining controls
The controls were selected from the 22,011 total adverse event
reports in females examined in the present study. The controls
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were selected for each type of case outcome examined by
including only those adverse event reports that did not include
the specific type of case outcome under study. Table 1 sum-
marizes the total number of controls for each type of case
outcome examined in VAERS.
Determining exposure
Exposure was determined in the present study based upon
HPV4 vaccine administration (VAERS code: 1098). It was
presumed that adverse event reports that included HPV4
vaccine were exposed and adverse event reports that did not
include HPV4 vaccine were unexposed.
Statistical analyses
The Fisher’s exact test contained in the StatsDirect (version
2.8.0) statistical software package was utilized for statistical
analyses, and a two-sided p value <0.05 was considered to be
statistically significant. The null hypothesis was that there
would be no difference in exposure to HPV4 vaccine among
cases and controls.
Results
Table 2 examines among cases with SAAEs and controls the
frequency of exposure to HPV4 vaccine administration in the
VAERS database. It was observed that cases with the out-
comes of gastroenteritis (odds ratio=4.6), arthritis (odds ra-
tio=2.5), systemic lupus erythematosus (odds ratio=5.3), vas-
culitis (odds ratio=4), alopecia (odds ratio=8.3), or CNS
conditions (odds ratio=1.8) were significantly more likely
than controls to have received HPV4 vaccine. It was observed
that cases with the outcomes of Guillain-Barre syndrome
(odds ratio=0.75) or thrombocytopenia (odds ratio=1.3) were
no more likely than controls to have received HPV4 vaccine.
Table 3 evaluates among cases with general health out-
comes and controls the frequency of HPV4 vaccine adminis-
tration in the VAERS database. It was observed that cases with
the outcomes of infection (odds ratio=0.72), conjunctivitis
(odds ratio=0.88), or diarrhea (odds ratio=1.01) were no
more likely than controls to have received HPV4 vaccine.
Table 4 examines the seriousness and timing of the SAAEs
that were significantly associated with HPV4 vaccine admin-
istration. It was observed among the SAAEs examined that
vasculitis (33 %), gastroenteritis (14.3 %), and systemic lupus
erythematosus (12.5 %) were associated with the highest
percentages of life-threatening outcomes. It was also observed
among the SAAEs examined that CNS conditions (34.6 %),
vasculitis (33 %), and arthritis (25 %) were associated with
highest percentages of permanent disabilities. Finally, the
median onset of symptoms for the SAAEs examined revealed
that vasculitis was associated with closest median onset of
symptoms following HPV4 vaccination (6 days), and arthritis
was associated with the longest median onset of symptoms
following HPV4 vaccination (55 days).
Discussion
The present epidemiological study of the VAERS database
evaluated the potential relationship between HPV4 vaccine
administration and the risk for various types of SAAEs. It was
observed that the SAAEs of gastroenteritis, arthritis, systemic
lupus erythematosus, vasculitis, alopecia, and CNS conditions
were associated with HPV4 vaccine administration, whereas
the SAAEs of Guillain-Barre syndrome and thrombocytope-
nia were not associated with HPV4 vaccine administration. In
addition, it was observed that the general health outcomes of
infection, conjunctivitis, and diarrhea were not associatedwith
HPV4 vaccine administration. The importance of these find-
ings is that the present study provides epidemiological evi-
dence to support an association between HPV4 vaccine ad-
ministration and specific SAAEs.
The results obtained are consistent with several previous
clinical studies. For example, researchers investigated the
Table 1 A summary of various types of cases and controls examined in
the present study
Outcome examined (VAERS code) Number
Serious autoimmune adverse events:
Gastroenteritis cases (10017888) 12
Controls 21,999
Arthritis (10003246 or 10039073) 56
Controls 21,955
Guillain-Barre syndrome (10018767) 97
Controls 21,914
Thrombocytopenia (10043554 or 10043561) 24
Controls 21,987
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association between HPV vaccination and autoimmune man-
ifestations compatible with systemic lupus erythematosus or
systemic lupus erythematosus-like disease in six women who
presented with such symptoms following HPV vaccination
[8]. These investigators reported that in their cases, several
common features were observed, such as personal or familial
susceptibility to autoimmunity or adverse response to a prior
dose of the vaccine, both of which may be associated with a
higher risk of post-vaccination autoimmunity. Favorable re-
sponse to immunosuppressant was observed in all patients,
and there was a temporal association between HPV vaccine
and the appearance of systemic lupus erythematosus-like con-
ditions. Similarly, other investigators observed a case series of
three women that had onset or exacerbation of lupus following
HPV immunization [9].
In contrast to the results observed in the present study,
Arnheim-Dahlstrom et al. [10] evaluated autoimmune, neu-
rological, and venous thromboembolic adverse events after
immunization of adolescent girls with HPV4 in Denmark
and Sweden. These investigators examined a cohort of 997,
Table 2 A summary of exposure to HPV4 vaccine exposure among SAAE cases and controls
Group examined Number of cases (%) Number of controls (%) Odds ratio (95 % CI) p value1
Gastroenteritis
Exposed 7 5117 4.6 (1.3–18.5) 0.019
Unexposed 5 16,882
Arthritis
Exposed 24 5,100 2.5 (1.4-4.3) 0.0018
Unexposed 32 16,855
Guillain-Barre syndrome
Exposed 18 5106 0.75 (0.42–1.3) 0.33
Unexposed 79 16,808
Thrombocytopenia
Exposed 7 5,117 1.3 (0.48-3.5) 0.47
Unexposed 17 16,870
Systemic lupus erythematosus
Exposed 8 5116 5.3 (1.5–20.5) 0.007
Unexposed 5 16,882
Vasculitis
Exposed 6 5118 4 (1.01–16.4) 0.049
Unexposed 5 16,882
Alopecia
Exposed 40 5084 8.3 (4.5–15.9) <0.0001
Unexposed 16 16,871
CNS conditions
Exposed 26 5098 1.8 (1.04–2.9) 0.033
Unexposed 49 16,838
1 The Fisher’s exact test was utilized
Table 3 A summary of exposure to HPV4 vaccine exposure among general health outcomes cases and controls
Group examined Number of cases (%) Number of controls (%) Odds ratio (95 % CI) p value1
Infection
Exposed 7 5117 0.72 (0.27–1.7) 0.57
Unexposed 32 16,855
Conjunctivitis
Exposed 4 5120 0.88 (0.29–2.7) 0.99
Unexposed 15 16,872
Diarrhea
Exposed 150 4974 1.01 (0.83–1.22) 0.92
Unexposed 489 16,398
1 The Fisher’s exact test was utilized
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585 girls aged 10–17, among whom 296,826 received a
total of 696,420 HPV4 vaccine doses. Unlike the present
study that examined adverse event reports to the VAERS
database, Arnheim-Dahlstrom et al. examined incident hos-
pital diagnosed autoimmune, neurological, and venous
thromboembolic events (53 different outcomes) up to
180 days after each HPV4 vaccine dose, and rate ratios of
the outcomes were adjusted for age, country, calendar year,
parental country of birth, education, and socioeconomic
status, comparing vaccinated and unvaccinated person-
time. These investigators observed that the rate ratios for
20 of 23 autoimmune events were not significantly in-
creased. Exposure to HPV4 vaccine was significantly as-
sociated with Behcet’s syndrome, Raynaud’s disease, and
type 1 diabetes, but these investigators described that each
of these three outcomes fulfilled only one of three
predefined signal strengthening criteria. In addition, these
investigators observed that the rate ratios for five neurolog-
ical events were not significantly increased, and there was
no association between exposure to HPV4 vaccine and
venous thromboembolism. It is interesting to note that
despite the number of individuals examined by Arnheim-
Dahlstrom et al., their study was significantly underpow-
ered to even examine many types of outcomes, and of those
outcomes examined, in many cases, relatively few out-
comes were observed in the HPV4-vaccinated group. This
may potentially be a consequence of the fact that the source
for detecting outcomes in the Arnheim-Dahlstrom et al.
study was from hospital records. It seems reasonable to
hypothesize that many of the conditions examined by
Arnheim-Dahlstrom et al. would not necessarily require
hospitalization, and worse still, even if the condition even-
tually might require hospitalization, the Arnheim-
Dahlstrom et al. study examined the diagnosis of the out-
come in a hospital within the first 181 days after vaccina-
tion. As a result, for many of the outcomes examined by
Arnheim-Dahlstrom et al. that overlap that with the out-
comes examined in the present study, it was observed that
there similar potential trends for outcomes in both studies
(i.e., odds ratio for vasculitis in VAERS=4 vs. adjusted rate
ratio in Arnheim-Dahlstrom study=1.55 or odds for sys-
temic lupus erythematosus in VAERS=5.3 vs. adjusted rate
ratio in Arnheim-Dahlstrom study=1.35), but none of the
outcomes were significantly associated with HPV4 vacci-
nation in the Arnheim-Dahlstrom et al. study.
Also in contrast to the present study findings, Chao et al.
[11] undertook an observation safety study of HPV4 in 189,
629 women who receive one or more doses of HPV4
vaccine between August 2006 and March 2008 for new
diagnoses of autoimmune conditions within 180 days fol-
lowing each dose of HPV vaccine. These investigators
identified new-onset autoimmune conditions among HPV
recipients by electronic medical records, but then the med-
ical records were reviewed by clinicians to confirm the
diagnosis and determine the date of onset (only 31–40 %
of the cases were confirmed as new onset). It was observed
that there was no cluster of disease onset in relations to
vaccination timing, dose sequence, or age was found for
any autoimmune condition. None of the incidence rate
ratios was significantly elevated except for Hashimoto’s
disease, but further investigation failed to reveal consistent
evidence for a safety signal for autoimmune thyroid condi-
tions. These investigators concluded that no autoimmune
safety signal was found in women vaccine with HPV4.
Once again, the Chao et al. [11] study, just like the previ-
ously discussed Arnheim-Dahlstrom et al. [10] study, was
apparently significantly underpowered to find potential au-
toimmune conditions associated with HPV vaccination,
since more than half of the new-onset autoimmune cases
identified from electronic medical records were subse-
quently eliminated from the study following review by
clinicians.
Strengths/limitations
The study design used to evaluate the relationship between
exposure and outcomewas a significant strength of the present
study. The method employed to examine VAERS ensured that
Table 4 A summary of SAAEs associated with HPV4 vaccination
Group examined (n) Life threatening (%)1 Permanent disability (%)1 Median onset of symptoms2
Gastroenteritis (7) 1 (14.3) 1 (14.3) 7
Arthritis (24) 1 (4.2) 6 (25) 55
Systemic lupus erythematosus (8) 1 (12.5) 1 (12.5) 19
Vasculitis (6) 2 (33) 2 (33) 6
Alopecia (40) 2 (5) 6 (15) 29.5
CNS conditions (26) 2 (7.7) 9 (34.6) 31
1 Some outcomes may have more than 1 occurrence in any single event report. If data are grouped by any of these items then the number in the may
exceed the total number of unique events and the associated percentage of total unique event reports will exceed 100 % in such cases
2 Calculated based upon those reports with a specified date of onset of symptoms after vaccination
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the exposures to the various types of vaccines studied oc-
curred prior to the outcomes described in the adverse event
reports, since those reporting the adverse outcomes associated
the outcomes with the vaccines listed in the adverse event
reports.
Another strength of the study was that the VAERS data
were collected independently of the study design used in the
present study. Among those reporting the adverse event re-
ports examined, it was highly unlikely that any of them could
have envisioned methods of analysis used to evaluate the
potential relationship between HPV4 vaccine and the adverse
events examined.
An additional strength of the present study was the speci-
ficity of the types of the SAAEs associated with HPV4 vac-
cine. Namely, despite the fact that a number of different types
of potential SAAEs were examined for the relationship with
HPV4 vaccine administration, it was observed that systemic
lupus erythematosus or systemic lupus erythematosus-like or
associated events were associated with HPV4 vaccine admin-
istration. These types of outcomes are biologically plausibly
associated with HPV infection and HPV4 vaccine
administration.
In addition, in further support of the phenomena observed
in the present study, an examination of the VAERS database
for adverse events for laboratory findings consistent with
systemic lupus erythematosus or systemic lupus
erythematosus-like or associated events revealed reports with
rheumatoid factor positive (VAERS code: 10039080) or anti-
nuclear antibody positive (VAERS code: 10060055) or
antiphospholipid antibodies positive (VAERS code:
10048678) in comparison to controls were significantly more
likely to be exposed to HPV4 vaccine than unexposed (odds
ratio=4.8, 95 % confidence interval=2.7–8.7, p<0.0001).
Also, among the SAAEs associated with HPV4 vaccine ad-
ministration, it was observed, consistent with the biological
plausible onset window for SAAEs following vaccination,
that the median onset of symptoms ranged between 6 and
55 days post-immunization.
However, the results of the present study may have a
number of potential limitations. It is possible the results ob-
served may have occurred from unknown biases or co-
founders present in the datasets examined. This seems unlike-
ly because a series of general health outcomes were examined,
and all were observed to be exposed to HPV4 vaccine at a
similar frequency as controls.
An additional potential limitation of the present study of
the VAERS database is that VAERS may have shortcom-
ings, such as underreporting, difficulty in determining caus-
al relationship, and a lack of precise denominators. Never-
theless, as previously described by investigators from the
CDC, almost all of these types of shortcomings would
apply equally to VAERS reports after vaccines adminis-
tered to similar populations [12]. The case–control method
employed in the present study ensured that all of the ad-
verse event reports examined in VAERS were administered
to similar populations (i.e., age and gender), and as a result,
examining the relative exposure to HPV4 vaccine among
the cases and controls identified from the adverse event
reports examined in VAERS should provide accurate rela-
tive qualitative and quantitative relationships between dif-
fering vaccine exposures and adverse outcomes. Addition-
ally, investigators previously employed a similar case–con-
trol study design to the one used in the present study to
successfully evaluate the potential relationship between
vaccine administration and SAAEs [13].
Another potential limitation of the present study is that the
results observed may be the result of statistical chance. How-
ever, such a possibility would be unlikely given the limited
number of statistical tests performed, the highly significant
results observed (most p values observed were <0.01), and the
consistency in the direction and magnitude of the results
observed.
Still, other potential limitations of the present study include
the possibilities that some of the individuals in VAERS may
have had more subtle adverse events that were not brought to
the attention of their healthcare providers, healthcare pro-
viders may have misdiagnosed some individuals, or some
vaccine exposures may not have been appropriately classified.
These limitations, while possibly present in the data examined
in the current study, should not have significantly impacted
the results observed because it is unclear how differential
application would have occurred based upon different expo-
sures among cases and controls. Moreover, misclassification
occurring in the data examined would tend to bias any results
observed toward the null hypothesis, since such effects would
result in individuals being placed in the wrong exposure and/
or outcome categories examined, and result in decreased
statistical power to determine true potential exposure-
outcome relationships.
In addition, another potential limitation of the present study
is that other sources of exposure among cases and controls
were not evaluated. It is possible that the findings may be the
result of other components of the vaccines studied which, in
isolation or synergistically, interacted with the HPV4 vaccine
examined.
Finally, the current study suffers from the potential
limitation that analyses were not conducted to further ex-
plore the cumulative dosing effects from HPV4 vaccine
administration or to compare HPV vaccine administration
in comparison to unvaccinated populations. In future stud-
ies, it would be worthwhile to further explore these
precise-timing and cumulative-doses phenomena. In addi-
tion, it would be valuable to evaluate other adverse events,
as well as other covariates such as race, prior medical
history, etc., that may further affect the magnitude of the
adverse effects found.
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Conclusion
In conclusion, the present study provides epidemiological
evidence supporting a significant relationship between
HPV4 vaccine administration and SAAEs. The results are
consistent with a number of previous case-series of SAAEs
observed following HPV4 vaccine administration, and are
also consistent with the known biological plausibility of vac-
cine administration to induce SAAEs in some vaccine recip-
ients. In light of the findings of the present study, we recom-
mend that additional studies be conducted to further evaluate
the potential biological mechanisms involved in HPV4
vaccine-associated SAAEs in animal model systems, and to
examine the potential epidemiological relationship between
HPV4 vaccine-associated SAAEs in other databases and
populations.
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